Regen Biopharma Inc (RGBP) 0.1789 $RGBP
Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
PR Newswire - Wed Dec 16, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact with the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating "a checkpoint inhibitor pill." Previously, the Company reported that the use of gene silencing of NR2F6 leads to induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign.
Regen BioPharma passes US FDA's clearance to initiate clinical trial of HemaXellerate for treating Aplastic anemia
M2 - Wed Dec 16, 4:27AM CST
Biotechnology company Regen BioPharma (OTCBB:RGBP) stated on Tuesday that it plans to begin clinical trials of its Investigational New Drug (IND) of HemaXellerate in Aplastic anemia patients following the US Food and Drug Administration approval.
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate
PR Newswire - Tue Dec 15, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today receipt of a communication from the U.S. Food and Drug Administration, allowing for initiation of clinical trials under its Investigational New Drug (IND) #15376.
Regen BioPharma Inc. Attracts Top Researchers to Scientific Advisory Board
PR Newswire - Tue Dec 01, 7:30AM CST
Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer and recruits five distinguished scientists to join advisory team
Regen BioPharma Inc. Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application
PR Newswire - Tue Nov 17, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) and (OTC Pink: RGBP) announced today the submission to the Food and Drug Administration (FDA) of data and responses to questions posed by the FDA with regards to HemaXellerate . The data package submitted contained the final preclinical toxicology experiments performed by Charles River Laboratories (NYSE: CRL) on behalf of Regen as well as details of the proposed clinical trial. Results of all studies demonstrated lack of toxicity and the Company is optimistic that all concerns presented by the FDA have been addressed and that the FDA will grant clearance to the Company to initiate clinical trials on HemXellerate. HemXellerate is a cellular drug being developed by the Company designed to heal damaged bone marrow
CRL: 77.82 (-1.56)
Regen BioPharma Initiates NR2F6 T Cell Immunotherapy Preclinical Program with Dr. Santosh Kesari, Director of Neuro-oncology at John Wayne Cancer Institute
PR Newswire - Thu Nov 12, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the initiation of preclinical studies evaluating utilization of NR2F6 gene silencing as a means of stimulating the immune system in cancer patients with Dr. Santosh Kesari, Professor of Neurosciences, Director of Neuro-Oncology, and Chair of Translational Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute. The studies will examine whether initial observations in mouse immune cells that NR2F6 silencing can be translated into human immune cells. If successful, these studies will serve as the basis for a new cancer immunotherapeutic drug candidate, which would be useful as a monotherapy or adjuvant with other cancer immune therapies.
Regen BioPharma Files Patent Application on Personalized Checkpoint Inhibitor Cancer Immunotherapy
PR Newswire - Wed Nov 04, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced the filing of a patent application covering gene silencing of NR2F6 (a Protein Coding Gene) in various immune cell populations as a means of selectively activating the immune system to kill cancer cells. Researchers at Regen BioPharma have previously demonstrated that NR2F6 is an inhibitor of T cell development and activation[1]. In addition, a recent independent publication showed that immune cells from mice lacking NR2F6 are capable of killing prostate cancer cells[2]. The current patent application integrates the Company's knowledge of NR2F6 function, with clinically-applicable gene silencing techniques to create a patient-specific immune based therapy.
Regen BioPharma elects Harry Lander, PhD as president
M2 - Wed Oct 14, 4:15AM CDT
Biotechnology company Regen BioPharma (OTCBB:RGBP)(OTC:RGBP) reported on Tuesday that it has elected Harry Lander, PhD as its new president.
Regen BioPharma Inc. Announces Appointment of Dr. Harry Lander as President
PR Newswire - Tue Oct 13, 7:30AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP, OTC: RGBP) today announced the appointment of Harry Lander, PhD as its new president. Dr. Lander will work closely with the Company's Chairman & CEO David Koos as Regen BioPharma prepares to take the next steps forward in small molecule and immuno-oncological therapeutics.
Regen BioPharma, Inc. Cancer Stem Cell Gene Target Shown to be a Key Mediator of Cancer Immune Surveillance by Independent Researchers
PR Newswire - Tue Sep 29, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today that an independent research laboratory has published that the cancer stem cell target gene NR2F6 is a key gene that controls anti-tumor immune surveillance. Regen BioPharma has several pieces of intellectual property related to NR2F6 including issued United States patent # 9,091,696, Modulation of NR2F6 and methods and uses thereof, that covers methods for identifying compounds that can modulate the function of NR2F6 in mammalian cells and several other applications with priority dates of 2008 including patent application # 14571262 that covers use of gene silenicing with short interfering nucleic acid (siNA) antisense, short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) for treatment for cancer.
Regen BioPharma, Inc. Director of Molecular Therapeutics to Speak at Stem Cell Conference Regarding Leukemia Research Being Conducted by the Company
PR Newswire - Mon Sep 28, 7:30AM CDT
Dr. Christine Ichim will present at Stem Cell Meeting on the Mesa
Regen BioPharma, Inc. Announces Positive Results from GLP Safety Study for HemaXellerate
PR Newswire - Fri Sep 25, 7:30AM CDT
Final Experiments Requested by FDA Completed
Entest BioMedical Updates Company Status and Future Plans
PR Newswire - Thu Sep 24, 9:30AM CDT
Entest BioMedical Inc. (PINK: ENTB) discussed the Company's current status and future plans.
Regen Biopharma Inc. Initiates Small Molecule Hit Validation Study on Cancer Stem Cell Target Gene
PR Newswire - Wed Sep 23, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that it has initiated studies for its small molecule drug discovery platform on its cancer stem cell target gene. These studies are expected to be completed within the next two months.
Regen BioPharma, Inc. Files Utility Patent Application on Immune Based Therapy for Cancer
PR Newswire - Wed Sep 16, 7:30AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) announced today the filing of a utility patent application with the United States Patent and Trademark Office covering a novel cancer immunotherapy which induces activation of dendritic cells inside the body in order to stimulate immune-based rejection of cancer. The application builds on Regen's existing expertise in the area of dendritic cells including publications together with scientific advisory board member Dr. Wei-Ping Min (1-3), Professor at the University of Western Ontario, as well as purchase of issued patent # 8,389,708.
Regen BioPharma, Inc. BORIS Gene Silencing Technology Successfully Utilized by Independent Researchers to Kill Breast Cancer and Colon Cancer Stem Cells
PR Newswire - Mon Aug 24, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells. The technology involves using RNA interference to block expression of the cancer-sustaining gene Brother of the Regulator of Imprinted Sites (BORIS) by a process termed "gene silencing".
Regen BioPharma Inc. Progresses in FDA Responses to dCellVax Clinical Trial Questions
PR Newswire - Mon Aug 10, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) updated shareholders regarding progress achieved in its ongoing experiments performed to address FDA questions on its Investigational New Drug Application (IND) #16200 for dCellVax. IND #16200 is an application to conduct a Phase I clinical trial of the Company's dCellVax immunotherapeutic product as a treatment for advanced breast cancer patients.
Regen BioPharma, Inc. Successfully Completes in Life Portion of Experiments Requested by FDA for HemaXellerate Pre-Clinical Study
PR Newswire - Tue Jul 21, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) announced today positive preliminary safety results from the in life portion of an experimental study requested by the US Food and Drug Administration (FDA) assessing toxicity in mice treated with high doses of HemaXellerate, a proprietary therapy under development by Regen Biopharma, Inc. After a 14 day observation period, male and female mice administered with higher than 10-fold the proposed human dose on a per kilogram basis exhibited no adverse effects. Regen expects to receive an audited report on full completion of the experiments in mid-September.
Regen BioPharma, Inc. Presents Preclinical Proof-of-Concept of DiffronC Effectiveness at the International Society for Stem Cell Research (ISSCR) Annual Meeting
PR Newswire - Tue Jul 14, 7:30AM CDT
Regen BioPharma Inc (OTCBB: RGBP) (OTC PINK: RGBP) announced today that Dr. Christine Ichim, the Company's Director of Molecular Therapeutics presented preclinical data regarding its DiffronC technology( a constituent of its Differentiation Therapy Platform) at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden on June 24th, 2015.
Regen BioPharma doses mice under its safety and tolerability study of HemaXellerate for aplastic anemia
M2 - Fri Jul 10, 3:36AM CDT
Biotechnology company Regen BioPharma (OTCBB:RGBP) (OTC PINK:RGBP) announced on Thursday the successful dosing of mice lacking an immune system under its safety and tolerability study with its proprietary aplastic anemia cell therapy drug candidate, HemaXellerate.
Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
PR Newswire - Wed Dec 16, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact with the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating "a checkpoint inhibitor pill." Previously, the Company reported that the use of gene silencing of NR2F6 leads to induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign.
Regen BioPharma passes US FDA's clearance to initiate clinical trial of HemaXellerate for treating Aplastic anemia
M2 - Wed Dec 16, 4:27AM CST
Biotechnology company Regen BioPharma (OTCBB:RGBP) stated on Tuesday that it plans to begin clinical trials of its Investigational New Drug (IND) of HemaXellerate in Aplastic anemia patients following the US Food and Drug Administration approval.
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate
PR Newswire - Tue Dec 15, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today receipt of a communication from the U.S. Food and Drug Administration, allowing for initiation of clinical trials under its Investigational New Drug (IND) #15376.
Regen BioPharma Inc. Attracts Top Researchers to Scientific Advisory Board
PR Newswire - Tue Dec 01, 7:30AM CST
Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer and recruits five distinguished scientists to join advisory team
Regen BioPharma Inc. Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application
PR Newswire - Tue Nov 17, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) and (OTC Pink: RGBP) announced today the submission to the Food and Drug Administration (FDA) of data and responses to questions posed by the FDA with regards to HemaXellerate . The data package submitted contained the final preclinical toxicology experiments performed by Charles River Laboratories (NYSE: CRL) on behalf of Regen as well as details of the proposed clinical trial. Results of all studies demonstrated lack of toxicity and the Company is optimistic that all concerns presented by the FDA have been addressed and that the FDA will grant clearance to the Company to initiate clinical trials on HemXellerate. HemXellerate is a cellular drug being developed by the Company designed to heal damaged bone marrow
CRL: 77.82 (-1.56)
Regen BioPharma Initiates NR2F6 T Cell Immunotherapy Preclinical Program with Dr. Santosh Kesari, Director of Neuro-oncology at John Wayne Cancer Institute
PR Newswire - Thu Nov 12, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the initiation of preclinical studies evaluating utilization of NR2F6 gene silencing as a means of stimulating the immune system in cancer patients with Dr. Santosh Kesari, Professor of Neurosciences, Director of Neuro-Oncology, and Chair of Translational Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute. The studies will examine whether initial observations in mouse immune cells that NR2F6 silencing can be translated into human immune cells. If successful, these studies will serve as the basis for a new cancer immunotherapeutic drug candidate, which would be useful as a monotherapy or adjuvant with other cancer immune therapies.
Regen BioPharma Files Patent Application on Personalized Checkpoint Inhibitor Cancer Immunotherapy
PR Newswire - Wed Nov 04, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced the filing of a patent application covering gene silencing of NR2F6 (a Protein Coding Gene) in various immune cell populations as a means of selectively activating the immune system to kill cancer cells. Researchers at Regen BioPharma have previously demonstrated that NR2F6 is an inhibitor of T cell development and activation[1]. In addition, a recent independent publication showed that immune cells from mice lacking NR2F6 are capable of killing prostate cancer cells[2]. The current patent application integrates the Company's knowledge of NR2F6 function, with clinically-applicable gene silencing techniques to create a patient-specific immune based therapy.
Regen BioPharma elects Harry Lander, PhD as president
M2 - Wed Oct 14, 4:15AM CDT
Biotechnology company Regen BioPharma (OTCBB:RGBP)(OTC:RGBP) reported on Tuesday that it has elected Harry Lander, PhD as its new president.
Regen BioPharma Inc. Announces Appointment of Dr. Harry Lander as President
PR Newswire - Tue Oct 13, 7:30AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP, OTC: RGBP) today announced the appointment of Harry Lander, PhD as its new president. Dr. Lander will work closely with the Company's Chairman & CEO David Koos as Regen BioPharma prepares to take the next steps forward in small molecule and immuno-oncological therapeutics.
Regen BioPharma, Inc. Cancer Stem Cell Gene Target Shown to be a Key Mediator of Cancer Immune Surveillance by Independent Researchers
PR Newswire - Tue Sep 29, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today that an independent research laboratory has published that the cancer stem cell target gene NR2F6 is a key gene that controls anti-tumor immune surveillance. Regen BioPharma has several pieces of intellectual property related to NR2F6 including issued United States patent # 9,091,696, Modulation of NR2F6 and methods and uses thereof, that covers methods for identifying compounds that can modulate the function of NR2F6 in mammalian cells and several other applications with priority dates of 2008 including patent application # 14571262 that covers use of gene silenicing with short interfering nucleic acid (siNA) antisense, short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) for treatment for cancer.
Regen BioPharma, Inc. Director of Molecular Therapeutics to Speak at Stem Cell Conference Regarding Leukemia Research Being Conducted by the Company
PR Newswire - Mon Sep 28, 7:30AM CDT
Dr. Christine Ichim will present at Stem Cell Meeting on the Mesa
Regen BioPharma, Inc. Announces Positive Results from GLP Safety Study for HemaXellerate
PR Newswire - Fri Sep 25, 7:30AM CDT
Final Experiments Requested by FDA Completed
Entest BioMedical Updates Company Status and Future Plans
PR Newswire - Thu Sep 24, 9:30AM CDT
Entest BioMedical Inc. (PINK: ENTB) discussed the Company's current status and future plans.
Regen Biopharma Inc. Initiates Small Molecule Hit Validation Study on Cancer Stem Cell Target Gene
PR Newswire - Wed Sep 23, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that it has initiated studies for its small molecule drug discovery platform on its cancer stem cell target gene. These studies are expected to be completed within the next two months.
Regen BioPharma, Inc. Files Utility Patent Application on Immune Based Therapy for Cancer
PR Newswire - Wed Sep 16, 7:30AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) announced today the filing of a utility patent application with the United States Patent and Trademark Office covering a novel cancer immunotherapy which induces activation of dendritic cells inside the body in order to stimulate immune-based rejection of cancer. The application builds on Regen's existing expertise in the area of dendritic cells including publications together with scientific advisory board member Dr. Wei-Ping Min (1-3), Professor at the University of Western Ontario, as well as purchase of issued patent # 8,389,708.
Regen BioPharma, Inc. BORIS Gene Silencing Technology Successfully Utilized by Independent Researchers to Kill Breast Cancer and Colon Cancer Stem Cells
PR Newswire - Mon Aug 24, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells. The technology involves using RNA interference to block expression of the cancer-sustaining gene Brother of the Regulator of Imprinted Sites (BORIS) by a process termed "gene silencing".
Regen BioPharma Inc. Progresses in FDA Responses to dCellVax Clinical Trial Questions
PR Newswire - Mon Aug 10, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) updated shareholders regarding progress achieved in its ongoing experiments performed to address FDA questions on its Investigational New Drug Application (IND) #16200 for dCellVax. IND #16200 is an application to conduct a Phase I clinical trial of the Company's dCellVax immunotherapeutic product as a treatment for advanced breast cancer patients.
Regen BioPharma, Inc. Successfully Completes in Life Portion of Experiments Requested by FDA for HemaXellerate Pre-Clinical Study
PR Newswire - Tue Jul 21, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) announced today positive preliminary safety results from the in life portion of an experimental study requested by the US Food and Drug Administration (FDA) assessing toxicity in mice treated with high doses of HemaXellerate, a proprietary therapy under development by Regen Biopharma, Inc. After a 14 day observation period, male and female mice administered with higher than 10-fold the proposed human dose on a per kilogram basis exhibited no adverse effects. Regen expects to receive an audited report on full completion of the experiments in mid-September.
Regen BioPharma, Inc. Presents Preclinical Proof-of-Concept of DiffronC Effectiveness at the International Society for Stem Cell Research (ISSCR) Annual Meeting
PR Newswire - Tue Jul 14, 7:30AM CDT
Regen BioPharma Inc (OTCBB: RGBP) (OTC PINK: RGBP) announced today that Dr. Christine Ichim, the Company's Director of Molecular Therapeutics presented preclinical data regarding its DiffronC technology( a constituent of its Differentiation Therapy Platform) at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden on June 24th, 2015.
Regen BioPharma doses mice under its safety and tolerability study of HemaXellerate for aplastic anemia
M2 - Fri Jul 10, 3:36AM CDT
Biotechnology company Regen BioPharma (OTCBB:RGBP) (OTC PINK:RGBP) announced on Thursday the successful dosing of mice lacking an immune system under its safety and tolerability study with its proprietary aplastic anemia cell therapy drug candidate, HemaXellerate.
